ClinicalTrials.gg
CompletedNCT07116512Updated Aug 11, 2025

A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants

A Phase 1 interventional study of Finerenone (BAY94-8862): intervention A and Finerenone (BAY94-8862): intervention B in Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent and Healthy Volunteers, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled May 2023, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Enrollment
18th of 23
60 · median 120
Started
2023
the only one that year
Phase 1
2 of 23
none open now
Registered
11th of 23
by date
Lead sponsor
8 of 23
Bayer

Among the 23 studies testing finerenone in Heart Failure, this one is the 18th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 1, and was the 11th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

In this bioequivalence study, healthy male participants took the study treatment finerenone in the form of one and two tablets of different strengths by mouth. "Bioequivalence" means that the researchers want to show similar blood levels of finerenone in the participants when they take the one tablet form of finerenone compared to the two tablets form. This study helped researchers learn more about a new finerenone tablet with higher strength, which is being developed to treat people who have heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40%.

HF with LVEF ≥ 40% is a condition which occurs when the left side of the heart does not pump blood out to the body as well as it should. Over time, the body does not get the amount of oxygen it needs. This can lead to shortness of breath and tiredness, making it harder for people to do their daily tasks.

Finerenone works by blocking a certain protein, called mineralocorticoid receptor. By doing this, finerenone reduces damage to kidneys, heart and blood vessels. It is available and approved for doctors to prescribe to people with chronic kidney disease together with type 2 diabetes.

The main objective of this study was to compare how much finerenone gets into the blood when the participants took the same amount of finerenone in the form of one and two tablets of different strengths by mouth.

Another objective of this study was to learn the degree to which medical problems that might be caused by finerenone can be tolerated (also called "tolerability") by the participants. These medical problems were also known as "adverse events". Doctors kept track of all adverse events that happened in the study, even if they did not think they might be related to the study treatments.

The study was conducted in a single-center, randomized, non-blinded, two-way crossover design in healthy male participants aged 18 to 55 years.

"Single-center" means at one research center or one hospital. "Randomized" means that the study participants were randomly (by chance) assigned to one of two sequences of treatments. "Non-blinded" means that both the participants and the study doctors and their team know what the participants will take. In a "two-way crossover" study, all the participants take all of the treatments, but in a different order. Each participant was in the study for approximately 4-6 weeks including a stay in the center for up to 6 days with 5 overnight stays.

In this study, each participant took finerenone twice by mouth on an empty stomach. They took finerenone in the form of one and two tablets of different strengths. The tablet form that was taken first depended on the treatment sequence to which the participants were assigned. There was a period of 3 days between the intake of the tablets.

Each participant served as his/her own control. This means that researchers made comparisons between the two tablet forms of finerenone within the same participant.

During the study, the doctors and their study team took blood and urine samples, did physical examinations, performed ECG and checked vital signs such as blood pressure, heart rate and body temperature.

Participants of this study were healthy and had no benefit from taking the study treatment finerenone. However, the study provided information on how to use the new tablet form of finerenone to treat patients with HF with LVEF ≥ 40% Specific measures had been put in place to counter and minimize the risks related to the conduct of this study. Information on safety of finerenone was already available from previous studies. Monitoring procedures, limitation of given doses and exclusion criteria had been defined. Blood samples were taken via an indwelling catheter (up to 15 times on the treatment days and once the day after). One screening visit was planned up to 28 days before the start of treatment and one visit was planned about 7 days after the end of treatment.

The benefit-risk assessment was considered positive and justified the conduct of the planned study in healthy participants.

03

Conditions studied

  • Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive, at the time of signing the .
  • Participants who were overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, body temperature, vital signs, and .
  • within the range 18.0 to 29.9 kg/m\^2 (inclusive) at the screening visit.
  • used by men and female partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Known to any study intervention (active substances or of the preparations) to be used in the study - including e.g., non- medicinal products, challenge agents, or rescue medication.
  • Medical disorder, condition or history of such that would impair the participant's ability to take part in or complete this study in the opinion of the investigator.
  • Diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study intervention(s) will not be normal.
  • Use of systemic or topical medicines or substances which might influence the study objectives.
  • Suspicion of drug or alcohol abuse.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    finerenone sequences: intervention A_intervention B

    Participants received intervention A first, with a washout period of at least 72 hours, participants then received intervention B

    Drug: Finerenone (BAY94-8862): intervention A · Drug: Finerenone (BAY94-8862): intervention B

  • Experimental
    finerenone sequences: intervention B_intervention A

    Participants received intervention B first, with a washout period of at least 72 hours, participants then received intervention A

    Drug: Finerenone (BAY94-8862): intervention A · Drug: Finerenone (BAY94-8862): intervention B

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax for plasma finerenone concentration

    Cmax: maximum concentration.

    Time frame: 0-24 h post dose

  2. AUC(0-tlast) for plasma finerenone concentration

    AUC = area under the curve, which was the total amount of finerenone in plasma

    Time frame: 0-24 h post dose

Secondary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs)

    AEs were considered to be treatment-emergent if they have started or worsened after administration up to 3 days after end of treatment with study intervention.

    Time frame: After first administration of study intervention up to 3 days after end of treatment with study intervention

07

Study locations

1 site
  • CRS Clinical Research Services Wuppertal GmbH
    Wuppertal, North Rhine-Westphalia 42113, Germany
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jul 2023, 2 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 11, 2025
StartActual
May 2, 2023
Primary completionActual
Jul 28, 2023
CompletionActual
Jul 28, 2023
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07116512
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
May 2, 2023
Primary completion
Jul 28, 2023
Completion
Jul 28, 2023
Last update
Aug 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion